Alkermes PLC (ALKS) Shares Bought by Asset Management One Co. Ltd.

Asset Management One Co. Ltd. grew its stake in shares of Alkermes PLC (NASDAQ:ALKS) by 6,353.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 234,377 shares of the company’s stock after buying an additional 230,745 shares during the quarter. Asset Management One Co. Ltd. owned 0.15% of Alkermes worth $11,924,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the company. FMR LLC grew its stake in shares of Alkermes by 0.4% during the second quarter. FMR LLC now owns 22,978,575 shares of the company’s stock valued at $1,332,068,000 after buying an additional 96,457 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Alkermes by 3.7% during the second quarter. Vanguard Group Inc. now owns 12,546,198 shares of the company’s stock valued at $727,303,000 after buying an additional 449,563 shares during the last quarter. Woodford Investment Management Ltd grew its stake in shares of Alkermes by 2.4% during the second quarter. Woodford Investment Management Ltd now owns 7,647,977 shares of the company’s stock valued at $443,353,000 after buying an additional 177,449 shares during the last quarter. Thornburg Investment Management Inc. grew its stake in shares of Alkermes by 39.8% during the third quarter. Thornburg Investment Management Inc. now owns 2,779,364 shares of the company’s stock valued at $141,303,000 after buying an additional 790,692 shares during the last quarter. Finally, Janus Henderson Group PLC grew its stake in shares of Alkermes by 13,784.0% during the second quarter. Janus Henderson Group PLC now owns 2,330,992 shares of the company’s stock valued at $135,128,000 after buying an additional 2,314,203 shares during the last quarter. 99.69% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Alkermes PLC (NASDAQ ALKS) opened at $52.62 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.72 and a current ratio of 3.05. Alkermes PLC has a 1-year low of $46.42 and a 1-year high of $63.40.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings data on Thursday, October 26th. The company reported $0.03 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.04. Alkermes had a negative net margin of 20.12% and a negative return on equity of 7.27%. The business had revenue of $217.40 million during the quarter, compared to analyst estimates of $231.29 million. During the same period last year, the business posted ($0.09) earnings per share. Alkermes’s quarterly revenue was up 20.6% compared to the same quarter last year. sell-side analysts forecast that Alkermes PLC will post -0.59 earnings per share for the current fiscal year.

In other Alkermes news, SVP James M. Frates sold 20,932 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $47.58, for a total value of $995,944.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Paul J. Mitchell sold 1,000 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $51.98, for a total transaction of $51,980.00. Following the completion of the sale, the director now owns 9,000 shares of the company’s stock, valued at $467,820. The disclosure for this sale can be found here. Insiders sold 109,364 shares of company stock valued at $5,355,310 over the last 90 days. 5.34% of the stock is currently owned by company insiders.

A number of analysts have recently weighed in on the stock. ValuEngine upgraded shares of Alkermes from a “sell” rating to a “hold” rating in a report on Friday, December 1st. Barclays lowered shares of Alkermes from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $66.00 to $50.00 in a report on Monday, October 16th. J P Morgan Chase & Co set a $78.00 target price on shares of Alkermes and gave the stock a “buy” rating in a report on Friday, October 27th. Jefferies Group set a $69.00 target price on shares of Alkermes and gave the stock a “buy” rating in a report on Friday, August 25th. Finally, Citigroup set a $62.00 target price on shares of Alkermes and gave the stock a “hold” rating in a report on Thursday, October 26th. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company. Alkermes currently has a consensus rating of “Hold” and an average price target of $63.55.

TRADEMARK VIOLATION NOTICE: “Alkermes PLC (ALKS) Shares Bought by Asset Management One Co. Ltd.” was published by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.com-unik.info/2017/12/16/alkermes-plc-alks-shares-bought-by-asset-management-one-co-ltd.html.

Alkermes Profile

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes PLC (NASDAQ:ALKS).

Institutional Ownership by Quarter for Alkermes (NASDAQ:ALKS)

What are top analysts saying about Alkermes? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alkermes and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit